BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 30707777)

  • 1. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
    Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addicts with chronic hepatitis C: difficult to reach, manage or treat?
    Zanini B; Benini F; Pigozzi MG; Furba P; Giacò E; Cinquegrana A; Fasoli M; Lanzini A
    World J Gastroenterol; 2013 Nov; 19(44):8011-9. PubMed ID: 24307794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
    Mak SK; Sin HK; Lo KY; Lo MW; Chan SF; Lo KC; Wong YY; Ho LY; Wong PN; Wong AKM
    Clin Exp Nephrol; 2017 Oct; 21(5):764-770. PubMed ID: 28083764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
    Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
    Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
    Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
    Hellard ME; Jenkinson R; Higgs P; Stoové MA; Sacks-Davis R; Gold J; Hickman M; Vickerman P; Martin NK
    Med J Aust; 2012 Jun; 196(10):638-41. PubMed ID: 22676879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies.
    Asselah T; Esmat G; Sanai FM; Goulis I; Messinger D; Bakalos G; Waked I
    Adv Ther; 2016 Oct; 33(10):1797-1813. PubMed ID: 27517563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
    Jung J; Kwon JH; Song GW; Tak EY; Kirchner VA; Lee SG
    J Gastrointest Surg; 2018 Aug; 22(8):1334-1342. PubMed ID: 29679347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection.
    Suzuki M; Minowa K; Tajiri H
    Ann Hepatol; 2018 Aug; 17(5):756-758. PubMed ID: 30145575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment.
    Lewis H; Kunkel J; Axten D; Dalton J; Gardner H; Tippett A; Wynne S; Wilkinson M; Foster GR
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1258-63. PubMed ID: 27487966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
    Flisiak R; Shiffman M; Arenas J; Cheinquer H; Nikitin I; Dong Y; Rana K; Srinivasan S
    PLoS One; 2016; 11(10):e0164563. PubMed ID: 27749900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.